Panel wants FDA to approve Xarelto as preventive stroke therapy

An FDA advisory panel endorsed the approval of anticoagulant Xarelto to prevent stroke in patients with atrial fibrillation. Earlier, agency staff questioned whether Xarelto is superior to standard drug warfarin. Xarelto developers Johnson & Johnson and Bayer expect an FDA decision in November.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ